Treatment of Advanced Emphysema with Emphysematous Lung Sealant (AeriSeal®)

Respiration - Tập 82 Số 1 - Trang 36-45 - 2011
Felix J.F. Herth1, Daniela Gompelmann1, Franz Stanzel2, R. Bonnet3, Jürgen Behr4, Bernd Schmidt5, H Magnussen6, Armin Ernst1
1Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg
2Lungenklinik Hemer, Pneumologie – Schwerpunkt Thorakale Endoskope, Hemer,
3Zentralklinik Bad Berka GmbH, Klinik für Pneumologie, Bad Berka,
4Medizinische Klinik und Poliklinik I, Pneumologie, Klinikum Grosshadern der LMU, München,
5Medizinische Klinik mit Schwerpunkt Infektiologie und Pneumologie, Charité, Berlin, and
6Zentrum für Pneumologie und Thoraxchirurgie GmbH, Krankenhaus Grosshansdorf, Grosshansdorf, Germany

Tóm tắt

<i>Background:</i> This report summarizes initial tests of an emphysematous lung synthetic polymer sealant (ELS) designed to reduce lung volume in patients with advanced emphysema. <i>Objectives:</i> The primary study objective was to define a therapeutic strategy to optimize treatment safety and effectiveness. <i>Methods:</i> ELS therapy was administered bronchoscopically to 25 patients with heterogeneous emphysema in an open-label, noncontrolled study at 6 centers in Germany. Treatment was performed initially at 2–4 subsegments. After 12 weeks, patients were eligible for repeat therapy to a total of 6 sites. Safety and efficacy were assessed after 6 months. Responses were evaluated in terms of changes from baseline in lung physiology, functional capacity, and health-related quality of life. Follow-up is available for 21 of 25 patients. <i>Results:</i> Treatment was well tolerated. There were no treatment-related deaths (i.e. within 90 days of treatment), and an acceptable short- and long-term safety profile. Physiological and clinical benefits were observed at 24 weeks. Efficacy responses were better among Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage III patients [n = 14; change in residual volume/total lung capacity (ΔRV/TLC) = –7.4 ± 10.3%; Δ forced expiratory volume in 1 s (ΔFEV<sub>1</sub>) = +15.9 ± 22.6%; change in forced vital capacity (ΔFVC) = +24.1 ± 22.7%; change in carbon monoxide lung diffusion capacity (ΔDL<i>CO)</i> = +19.3 ± 34.8%; change in 6-min walk test (Δ6MWD) = +28.7 ± 59.6 m; change in Medical Research Council Dyspnea (ΔMRCD) score = –1.0 ± 1.04 units; change in St. George’s Respiratory Questionnaire (ΔSGRQ) score = –9.9 ± 15.3 units] than for GOLD stage IV patients (n = 7; ΔRV/TLC = –0.5 ± 6.4%; ΔFEV<sub>1</sub> = +2.3 ± 12.3%; ΔFVC = +2.6 ± 21.1%; ΔDL<i>CO</i> = –2.8 ± 17.2%; Δ6MWD = +28.3 ± 58.4 m; ΔMRCD = 0.3 ± 0.81 units; ΔSGRQ = –6.7 ± 7.0 units). <i>Conclusions:</i> ELS therapy shows promise for treating patients with advanced heterogeneous emphysema. Additional studies to assess responses in a larger cohort with a longer follow-up are warranted.

Từ khóa


Tài liệu tham khảo

10.1097%2FMCP.0b013e328012e053

10.1053%2Fj.semtcvs.2007.05.008

10.1164%2Frccm.200407-961OC

10.1016%2FS0140-6736%2803%2912762-6

10.1378%2Fchest.129.3.518

10.1016%2Fj.jtcvs.2003.10.005

10.1016%2Fj.jtcvs.2007.05.040

10.1016%2FS0003-4975%2802%2904553-8

10.1056%2FNEJMoa11798

10.1056%2FNEJMoa030287

10.1183%2F09031936.00099306

10.1164%2Frccm.2412005

10.1513%2Fpats.200708-117ET

10.1378%2Fchest.130.1.190

10.1016%2Fj.jtcvs.2006.06.051

10.1378%2Fchest.113.4.890

10.1016%2FS0022-5223%2896%2970439-7

10.1016%2FS1010-7940%2801%2900845-4

10.1016%2FS0003-4975%2897%2900550-X

Thông tin
Thông tin xuất bản

Respiration

Tập 82 Số 1

36-45

Thông tin tác giả